Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

ENROLLING
Protocol # :
25-264
Conditions
Mantle Cell Lymphoma
B Cell Lymphoma
Phase
III
Disease Sites
Non-Hodgkin Lymphoma
Principal Investigator
Ryan, Christine, E.
Site Research Nurses
Ali, Ijaabo
Bravo, Caitlin
Cyr, Virgina, Brigham
Kats, Vanessa
Mezitt, Anna
Normilus, Samantha
Patterson, Victoria
Re, Sandra

Trial Description

The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus
zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell
lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib
versus zanubrutinib plus placebo.

Eligibility Requirements

Inclusion Criteria:

- Histologically locally confirmed diagnosis of MCL based on the World Health
Organization 2022 classification of Haematolymphoid Tumors (WHO-HAEM5), or based on
International Consensus Classification (ICC)

- Ability to provide archival or fresh tumor tissue for retrospective central
confirmation of MCL diagnosis

- Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal
antibody (mAb)-based immunotherapy or chemoimmunotherapy and requiring treatment in
the opinion of the investigator

- Relapsed or refractory disease after the last line of therapy

- Measurable disease defined as ≥ 1 nodal lesion that is > 1.5 cm in longest diameter,
or ≥ 1 extranodal lesion that is > 1 cm in longest diameter

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2

- Adequate organ function

Exclusion Criteria:

- Prior therapy with B-cell lymphoma-2 inhibitor (BCL2i)

- Prior therapy with BTK degraders

- Prior therapy with covalent or non-covalent Bruton tyrosine kinase inhibitor (BTKi)
unless the participant was intolerant of non-zanubrutinib covalent or non-covalent
BTKi. Participants with refractory disease to BTKi therapy or relapse attributed to
failure of BTKi therapy are ineligible.

- Prior autologous stem cell transplantation or chimeric antigen receptor T-cell
therapy within 3 months before first dose of study drug

- Prior allogeneic stem cell transplant within 6 months of the first dose of the study
drug

- Known central nervous system involvement by lymphoma

- Clinically significant cardiovascular disease

- History of stroke or intracranial hemorrhage within 6 months before first dose of
study drug

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

25-264